Search results for "LIPIDE"

showing 10 items of 532 documents

Exome sequencing in suspected monogenic dyslipidemias.

2015

Background— Exome sequencing is a promising tool for gene mapping in Mendelian disorders. We used this technique in an attempt to identify novel genes underlying monogenic dyslipidemias. Methods and Results— We performed exome sequencing on 213 selected family members from 41 kindreds with suspected Mendelian inheritance of extreme levels of low-density lipoprotein cholesterol (after candidate gene sequencing excluded known genetic causes for high low-density lipoprotein cholesterol families) or high-density lipoprotein cholesterol. We used standard analytic approaches to identify candidate variants and also assigned a polygenic score to each individual to account for their burden of commo…

MaleSettore MED/09 - Medicina InternaMedical BiotechnologyDNA sequencing; exome; exome sequencing; genetics human; lipids; mendelian geneticsBiologyCardiorespiratory Medicine and HaematologyNovel genelipidsmendelian geneticsGene mappingClinical ResearchGenetics2.1 Biological and endogenous factorsHumansgeneticsExomeDNA sequencinghumanAetiologyMendelian disordersExomeGenetics (clinical)Exome sequencingDyslipidemiasGeneticsInborn ErrorsHuman GenomeHigh-Throughput Nucleotide SequencingAtherosclerosisMetabolismCardiovascular System & Hematologylipids (amino acids peptides and proteins)DNA sequencing; exome; genetics; human; lipidsFemalegeneticCardiology and Cardiovascular Medicineexome sequencingexomeMetabolism Inborn ErrorsCirculation. Cardiovascular genetics
researchProduct

Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients

2014

Abstract HDL-increasing drugs such as fenofibrate and niacin have failed to decrease the cardiovascular risk in patients with type 2 diabetes. Drug-mediated quantitative and qualitative HDL modifications could be involved in these negative results. To evaluate the quantitative and qualitative effects of niacin and fenofibrate on HDL in patients with type 2 diabetes, a prospective, randomised controlled intervention trial was conducted. Thirty type 2 diabetic patients with low HDL were randomised to receive either fenofibrate (FFB) or niacin + laropiprant (ERN/LPR) as an add-on to simvastatin treatment for 12 weeks according to a crossover design. At the basal point and after each interventi…

MaleSimvastatinIndolesTime FactorsType 2 diabetesHigh-Density Lipoproteins Pre-betaAntioxidantsBasal (phylogenetics)chemistry.chemical_compoundFenofibrateProspective StudiesHypolipidemic AgentsFenofibrateMiddle AgedOxidantsPON1Up-RegulationTreatment OutcomeDrug Therapy CombinationFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicineNiacinmedicine.drugAdultmedicine.medical_specialtyNiacinbehavioral disciplines and activitiesInternal medicinemedicineHumansMetabolomicsParticle SizeAgedDyslipidemiasbusiness.industryCholesterolCholesterol HDLnutritional and metabolic diseasesmedicine.diseaseCrossover studyCross-Sectional StudiesEndocrinologyDiabetes Mellitus Type 2chemistrySpainSimvastatinHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkersAtherosclerosis
researchProduct

Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men-a randomized trial.

2013

Context and Objective Investigating the effects of lipid-lowering drugs on HDL subclasses has shown ambiguous results. This study assessed the effects of ezetimibe, simvastatin, and their combination on HDL subclass distribution. Design and Participants A single-center randomized parallel 3-group open-label study was performed in 72 healthy men free of cardiovascular disease with a baseline LDL-cholesterol of 111±30 mg/dl (2.9±0.8 mmol/l) and a baseline HDL-cholesterol of 64±15 mg/dl (1.7±0.4 mmol/l). They were treated with ezetimibe (10 mg/day, n = 24), simvastatin (40 mg/day, n = 24) or their combination (n = 24) for 14 days. Blood was drawn before and after the treatment period. HDL subc…

MaleSimvastatinlcsh:MedicinePharmacologyBiochemistryLipoprotein MetabolismVascular MedicineSubclasslaw.inventionchemistry.chemical_compoundHigh-density lipoproteinRandomized controlled triallawMedicine and Health SciencesMedicinelcsh:ScienceHypolipidemic AgentsMultidisciplinaryHealthy VolunteersResearch DesignDrug Therapy Combinationlipids (amino acids peptides and proteins)Lipoproteins HDLResearch Articlemedicine.drugAdultmedicine.medical_specialtylipid-lowering drugs high-density lipoprotein healthy menDrug Research and DevelopmentClinical Research DesignLipoproteinsHypercholesterolemiaCardiologyAdipokineContext (language use)Research and Analysis MethodsCardiovascular PharmacologyAdipokinesEzetimibeInternal medicineHumansClinical TrialsPharmacologybusiness.industryCholesterollcsh:RBiology and Life SciencesProteinsnutritional and metabolic diseasesEzetimibeAtherosclerosisGlucoseEndocrinologychemistrySimvastatinAzetidineslcsh:QClinical MedicinebusinessBiomarkersPLoS ONE
researchProduct

Differential proto-oncogene mRNA induction from rats treated with peroxisome proliferators

1990

After experimental treatment of rats with clofibrate or ciprofibrate, two peroxisomes proliferators with hypolipidemic activity, RNAs were prepared from liver, kidney, heart and brain; hybridization was done with DNA probes for c-myc and c-Ha-ras oncogenes and for cyanide insensitive Acyl CoA oxidase, a peroxisomal protein. c-myc mRNA is highly abundant in liver and at a lower extent in kidney, especially after treatment with ciprofibrate; clofibrate also allows a c-myc mRNA increase, but at a lower extent. c-Ha-ras, which is already expressed in all tested tissues from control animals, is stimulated by clofibrate and ciprofibrate treatments. Comparatively these compounds stimulate the cyan…

MaleSomatic cellGenes mycBiophysicsBiologyKidneyMicrobodiesBiochemistryClofibric AcidProto-OncogenesmedicineAnimalsAcyl-CoA oxidaseClofibrateRNA MessengerMolecular BiologyHypolipidemic AgentsKidneyMessenger RNAClofibrateOncogeneFibric AcidsCell BiologyPeroxisomeMolecular biologyRats Inbred F344RatsGenes rasmedicine.anatomical_structureGene Expression RegulationLiverOrgan SpecificityAcyl-CoA OxidaseCiprofibrateOxidoreductasesmedicine.drugBiochemical and Biophysical Research Communications
researchProduct

White blood cell counts as risk markers of developing metabolic syndrome and its components in the Predimed study.

2013

Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; TRIAL REGISTRATION Controlled-Trials.comISRCTN35739639. BACKGROUND The Metabolic Syndrome (MetS) is a cluster of metabolic abnormalities that includes hyperglucemia, hypertension, dyslipidemia and central obesity, conferring an increased risk of cardiovascular disease. The white blood cell (WBC) count has been proposed as a marker for predicting cardiovascular risk. However, few prospective studies have evaluated the relationship between WBC subtypes and risk of MetS. METHODS Participants were recruited from seven PREDIMED study centers. Both a baseline cross-sectional (n = 4,377) and a prospe…

MaleSíndrome metabòlicaMediterranean dietNeutrophilsEpidemiologyEstudios transversalesMetabolic disorders:Named Groups::Persons::Age Groups::Adult::Aged::Aged 80 and over [Medical Subject Headings]Disease:Named Groups::Persons::Age Groups::Adult::Middle Aged [Medical Subject Headings]Diet Mediterranean:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]Leukocyte CountLymphocitesRisk FactorsBlood plasmaPathologyMedicineProspective StudiesProspective cohort studyAged 80 and overMetabolic SyndromeClinical ChemistryMultidisciplinary:Analytical Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Nutrition Therapy::Diet Therapy::Diet Mediterranean [Medical Subject Headings]QRMiddle AgedMetabolic syndromeClinical Laboratory Sciences1932-6203:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cross-Sectional Studies [Medical Subject Headings]medicine.anatomical_structureCholesterolCardiovascular diseasesCardiovascular DiseasesMedicineWhite blood cellsFemalePublic HealthEnfermedades cardiovascularesResearch Articlemedicine.medical_specialty:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies [Medical Subject Headings]Recuento de linfocitosScience:Check Tags::Male [Medical Subject Headings]Mediterranean cookingDiagnostic MedicineInternal medicineWhite blood cell:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cell Count::Blood Cell Count::Leukocyte Count::Lymphocyte Count [Medical Subject Headings]Cuina mediterràniaHumansLymphocyte CountObesity:Named Groups::Persons::Age Groups::Adult::Aged [Medical Subject Headings]:Diseases::Cardiovascular Diseases [Medical Subject Headings]Cardiovascular Disease EpidemiologyAged:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Metabolic Syndrome X [Medical Subject Headings]business.industryMalalties cardiovascularsRecuento de leucocitosSíndrome X metabólicomedicine.diseaseObesityLong-Term CareDieta mediterránea:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques::Cytological Techniques::Cell Count::Blood Cell Count::Leukocyte Count [Medical Subject Headings]Biomarker EpidemiologyCross-Sectional Studies:Check Tags::Female [Medical Subject Headings]GeriatricsImmunologyClinical ImmunologyPreventive MedicineMetabolic syndrome:Anatomy::Cells::Blood Cells::Leukocytes::Granulocytes::Neutrophils [Medical Subject Headings]businessDyslipidemiaBiomarkersGeneral Pathology
researchProduct

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.

2007

Objective— Apolipoprotein A5 ( APOA5 ) is a key determinant of plasma triglyceride (TG) concentrations. Genetic variation at the APOA5 locus could be responsible for some of the observed differences in response to fenofibrate therapy. Methods and Results— We examined the association between tag SNPs (−1131T>C and 56C>G) at APOA5 and TG and HDL-C response to fenofibrate and a postprandial lipid challenge in 791 men and women participating in the GOLDN study. After 3-week drug treatment, APOA5 56G carriers displayed significant decrease in TG ( P =0.006), and increase in HDL-C ( P =0.002) levels relative to their basal values in the fasting state when compared with noncarriers (a TG re…

MaleTime FactorsApolipoprotein BAdministration Oralchemistry.chemical_compoundFenofibrateGene FrequencyApolipoprotein a5Hypolipidemic AgentsAged 80 and overFenofibratebiologyMiddle AgedPostprandial PeriodPostprandialTreatment OutcomeArea Under CurveFemaleCardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyGuanineAdolescentGenotypeSingle-nucleotide polymorphismHyperlipidemiasPolymorphism Single NucleotideCytosineInternal medicinemedicineHumansParticle SizeApolipoproteins ATriglyceridesAgedTriglyceridebusiness.industryCholesterolCholesterol HDLCholesterol LDLDrug interactionLipid MetabolismDietary FatsUnited StatesEndocrinologychemistryApolipoprotein A-Vbiology.proteinbusinessThymineArteriosclerosis, thrombosis, and vascular biology
researchProduct

Endotoxin accelerates atherosclerosis independent of complement activation

2008

a Central Laboratory Animal Facility b Institute of Clinical Chemistry and Laboratory Medicine c Institute of Medical Microbiology and Hygiene, Johannes Gutenberg University, Mainz, Germany d Klinik fur Gefaschirurgie und Nierentransplantation, Heinrich Heine Universitatsklinik, Dusseldorf, Germany e Zentrum fur Medizin und Biowissenschaften, Forschungszentrum, Borstel, Germany f Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland g Department of Molecular Pathology, Graduate School of Medicine and Engineering, University of Yamanashi, Japan

MaleTime FactorsLibrary scienceHyperlipidemiasHematologyBiologyAtherosclerosisComplement C6Central laboratoryEndotoxinsC-Reactive ProteinCholesterolImmunologyAnimalsHumansFemaleRabbitsComplement ActivationTriglyceridesAnimal facilityThrombosis Research
researchProduct

Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: insights from Italian general practice

2018

Background and aims: Statin utilization and lipid goal achievement were estimated in a large sample of Italian patients at high/very-high cardiovascular (CV) risk. Methods: Patients aged ≥18 years with a valid low-density lipoprotein cholesterol (LDL-C) measurement in 2015 were selected from the IMS Health Real World Data database; non-high-density lipoprotein cholesterol (non-HDL-C) was assessed in those with available total cholesterol measurements. Index dates were defined as the last valid lipid measurement in 2015. Patients were hierarchically classified into mutually exclusive risk categories: heterozygous familial hypercholesterolemia (primary and secondary prevention), atheroscler…

MaleTime FactorsSettore MED/09 - Medicina InternaDatabases FactualGeneral PracticeFamilial hypercholesterolemiaDisease030204 cardiovascular system & hematology0302 clinical medicineRisk FactorsCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; StatinMedicine030212 general & internal medicinePractice Patterns Physicians'StrokeAged 80 and overLipid MeasurementMiddle AgedCardiovascular diseaseNon-high-density lipoprotein cholesterolCholesterolTreatment OutcomeItalyCardiovascular DiseasesCohortPractice Guidelines as Topiclipids (amino acids peptides and proteins)FemaleGuideline AdherenceCardiology and Cardiovascular Medicinemedicine.medical_specialtyAcute coronary syndromeStatinCardiovascular disease; Low-density lipoprotein cholesterol; Non-high-density lipoprotein cholesterol; Prevention; Statin; Cardiology and Cardiovascular Medicinemedicine.drug_classRisk Assessment03 medical and health sciencesDiabetes mellitusInternal medicineHumansLow-density lipoprotein cholesterolAgedDyslipidemiasRetrospective Studiesbusiness.industryPreventionStatinCholesterol LDLmedicine.diseaseHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessBiomarkers
researchProduct

Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2)

2001

X-linked adrenoleukodystrophy (X-ALD) is a neurodegenerative disease due to a defect in the ABCD1 (ALD) gene. ABCD1, and the two close homologues ABCD2 (ALDR) and ABCD3 (PMP70), are genes encoding ATP-binding cassette half-transporters of the peroxisomal membrane. As overexpression of the ABCD2 or ABCD3 gene can reverse the biochemical phenotype of X-ALD (reduced beta-oxidation of very-long-chain fatty acids), pharmacological induction of these partially redundant genes may represent a therapeutic approach to X-ALD. We previously reported that the ABCD2 and ABCD3 genes could be strongly induced by fibrates, which are hypolipidaemic drugs and peroxisome-proliferators in rodents. We provide e…

MaleTranscription GeneticMolecular Sequence DataResponse elementReceptors Cytoplasmic and NuclearATP-binding cassette transporterATP Binding Cassette Transporter Subfamily DBiochemistryMiceFenofibrateABCD3Sequence Homology Nucleic AcidABCD2medicineAnimalsHumansRats WistarAdrenoleukodystrophyPromoter Regions GeneticGeneHypolipidemic AgentsMice KnockoutBase SequencebiologyDNATransfectionPeroxisomemedicine.diseaseMolecular biologyRatsGene Expression Regulationbiology.proteinATP-Binding Cassette TransportersAdrenoleukodystrophyTranscription FactorsEuropean Journal of Biochemistry
researchProduct

Effects of Rosiglitazone on Fasting and Postprandial Low- and High-Density Lipoproteins Size and Subclasses in Type 2 Diabetes

2010

Rosiglitazone may increase cardiovascular risk in patients with type 2 diabetes. Yet, its effects on atherogenic dyslipidemia are still not fully elucidated. In a prospective open-label study rosiglitazone (4 mg/day for 12 weeks) was added to a maximum of 2 oral antidiabetic drugs in 18 diabetic patients. We evaluated the effects on plasma lipids before and after an oral fat load. The size and subclasses of low-density lipoprotein (LDL) and high-density lipoprotein (HDL) were also determined (by gradient gel electrophoresis). Rosiglitazone improved glycosylated hemoglobin ([HbA1c] P = .0023), without significant effects on fasting and postprandial plasma lipids. Fasting LDL size increased …

Malehigh-density lipoproteinsmedicine.medical_specialtyType 2 diabetes030204 cardiovascular system & hematologysizeStatistics NonparametricRosiglitazone03 medical and health sciences0302 clinical medicineDiabetes mellitusInternal medicinemedicinelow-density lipoproteinsHumansHypoglycemic AgentsProspective Studies030212 general & internal medicineGlycated Hemoglobindiabetesbusiness.industryFastingMiddle AgedPostprandial Periodmedicine.diseaseLipids3. Good healthLipoproteins LDLPostprandialEndocrinologyDiabetes Mellitus Type 2FemaleThiazolidinedioneslipids (amino acids peptides and proteins)HemoglobinsubclassesLipoproteins HDLCardiology and Cardiovascular MedicineRosiglitazonebusinessPioglitazoneDyslipidemiamedicine.drugLipoprotein
researchProduct